Cuproptosis: Mechanism, role, and advances in urological malignancies

Prostate, bladder, and kidney cancers are the most common malignancies of the urinary system. Chemotherapeutic drugs are generally used as adjuvant treatment in the middle, late, or recurrence stages after surgery for urologic cancers. However, traditional chemotherapy is plagued by problems such as...

Full description

Saved in:
Bibliographic Details
Published in:Medicinal research reviews 2024-07, Vol.44 (4), p.1662-1682
Main Authors: Wu, Jialong, He, Jide, Liu, Zenan, Zhu, Xuehua, Li, Ziang, Chen, Anjing, Lu, Jian
Format: Article
Language:English
Subjects:
Animals
Cancer therapies
Cell death
Chemotherapy
Copper
Copper - metabolism
cuproptosis
Homeostasis
Humans
mechanism
Prostate cancer
therapy
Urologic Neoplasms - drug therapy
Urologic Neoplasms - metabolism
Urological cancer
urological tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate, bladder, and kidney cancers are the most common malignancies of the urinary system. Chemotherapeutic drugs are generally used as adjuvant treatment in the middle, late, or recurrence stages after surgery for urologic cancers. However, traditional chemotherapy is plagued by problems such as poor efficacy, severe side effects, and complications. Copper‐containing nanomedicines are promising novel cancer treatment modalities that can potentially overcome these disadvantages. Copper homeostasis and cuproptosis play crucial roles in the development, adaptability, and therapeutic sensitivity of urological malignancies. Cuproptosis refers to the direct binding of copper ions to lipoylated components of the tricarboxylic acid cycle, leading to protein oligomerization, loss of iron–sulfur proteins, proteotoxic stress, and cell death. This review focuses on copper homeostasis and cuproptosis as well as recent findings on copper and cuproptosis in urological malignancies. Furthermore, we highlight the potential therapeutic applications of copper‐ and cuproptosis‐targeted therapies to better understand cuproptosis‐based drugs for the treatment of urological tumors in the future.
ISSN:0198-6325
1098-1128
1098-1128
DOI:10.1002/med.22025